Current Antipsychotics

Langue : anglais

Edité par Springer, 2014

3642445470 / 9783642445477

Série : Livre 43 sur 124 - Handbook of Experimental Pharmacology

Vendeur : AHA-BUCH GmbH, Einbeck, AllemagneAHA-BUCH GmbH

Vendeur avec une évaluation de 5 étoiles

Vendeur AbeBooks depuis 14 août 2006

Afficher les articles de ce vendeur
Livre broché

Etat: Neuf

EUR 342,92

EUR 30,50 expédition 
Expédition depuis Allemagne vers Etats-Unis

Quantité disponible : 1 disponible(s)

Ajouter au panier
Retours gratuits sous 30 jours

Item description from seller

Druck auf Anfrage Neuware - Printed after ordering - Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all. Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting ourdecision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders.Gerhard Gross, Ludwigshafen, GermanyMark A. Geyer, La Jolla, CAThis volume willtry to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

N° de réf. du vendeur 9783642445477

Titre
Current Antipsychotics
Auteur
Mark A. Geyer
Éditeur
Springer
Année de publication
2014
État de l'article
Neu
Reliure
Taschenbuch
Langue
anglais
ISBN à 10 chiffres
3642445470
ISBN à 13 chiffres
9783642445477
Poids de l'article
645 grammes
Dimensions
235x155x24 mm
Série
Livre 43 sur 124: Handbook of Experimental Pharmacology

AHA-BUCH GmbH

Einbeck, Allemagne

Vendeur avec une évaluation de 5 étoiles

Vendeur AbeBooks depuis 14 août 2006

Frais d'expédition de Allemagne vers Etats-Unis

Article5 à 7 jours ouvrés7 à 10 jours ouvrés
Premier articleEUR 30,50EUR 30,50
Les délais de livraison sont fixés par les vendeurs et varient en fonction du transporteur et du lieu. Les commandes transitant par les douanes peuvent être retardées et les acheteurs sont responsables de tous les droits ou frais associés. Les vendeurs peuvent vous contacter au sujet de frais supplémentaires afin de couvrir toute augmentation des coûts d'expédition de vos articles.

Modes de paiement

  • Visa
  • Mastercard
  • American Express
  • Carte Bleue
  • Apple Pay
  • Google Pay
  • Chèque
  • Paypal
  • Virement bancaire

Description de la boutique

Das Unternehmen AHA-BUCH GmbH: Seit der Gründung von AHA-BUCH im Juli 2005 ist unser Hauptziel, zufriedenen Kunden so schnell und so preisgünstig wie möglich ihren Bücherwunsch zu erfüllen. Unsere Firma beschäftigt 16 Mitarbeiter, die nur ein Ziel kennen: den Kunden und seine Wünsche! Auf über 3700 m2 Fläche haben wir über 100.000 Bücher, Modernes Antiquariat und Spiele auf Lager.

Spécialité

Kinderbücher & Kinderhör Casetten, German Books, Software, Natur & Tiere, Ratgeber, Sachbücher, Englische Bücher, Medizin & Gesundheit, Universität & Studium

Profil professionnel du vendeur

AHA-BUCH GmbH

Garlebsen 48
Einbeck, Allemagne 37574